GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Theragen Etex Co Ltd (XKRX:066700) » Definitions » Forward Dividend Yield %

Theragen Etex Co (XKRX:066700) Forward Dividend Yield % : 0.00% (As of May. 28, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Theragen Etex Co Forward Dividend Yield %?

As of today (2025-05-28), the Forward Annual Dividend Yield of Theragen Etex Co is 0.00%.

As of today (2025-05-28), the Trailing Annual Dividend Yield of Theragen Etex Co is 0.00%.

XKRX:066700's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.785
* Ranked among companies with meaningful Forward Dividend Yield % only.

Theragen Etex Co's Dividends per Share for the three months ended in Mar. 2025 was ₩0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Theragen Etex Co's Forward Dividend Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Theragen Etex Co's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theragen Etex Co's Forward Dividend Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Theragen Etex Co's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Theragen Etex Co's Forward Dividend Yield % falls into.


;
;

Theragen Etex Co Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Theragen Etex Co  (XKRX:066700) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Theragen Etex Co Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Theragen Etex Co's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Theragen Etex Co Business Description

Traded in Other Exchanges
N/A
Address
58, Sandan-ro 68-gil, Danwon-gu, Gyeonggi-do, Ansan-si, KOR
Theragen Etex Co Ltd is a Korea-based company mainly engaged in the manufacturing and selling of finished pharmaceutical products and providing genome sequencing services. It also provides healthcare services. The company's operating segments include its Pharmaceutical business and the Healthcare and Genome Analysis Business. A majority of its revenue is generated from the Pharmaceutical Business which involves the manufacturing and sales of specialized and general medicine along with new drug research and development. The Healthcare and Genome Analysis Business involves DNA sequence analysis, RNA mutation genome analysis and decoding, and the distribution of non-prescription drugs for healthcare purposes. Geographically, the company derives its key revenue from the domestic market.

Theragen Etex Co Headlines

No Headlines